Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
13F holders, Q4 2025 (December 31)16holders +1
5new positions
3sold out
$1.00avg. 13F price*
At the end of Q4 2025, 16 institutions reported holding Biomarin Pharmaceutical (bmrn 1.25 05/15/27) in their 13F filings, up 1 from Q3 2025. 5 opened new positions and 3 sold out. The largest holders were Focus Partners Wealth ($3.3M), State of Wisconsin Investment Board ($2.9M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.8M).
- Company
- Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
- CUSIP
- 09061GAK7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $3.8M |
| Exits | 3 | $46K |
All 13F filers, Q3 2025 → Q4 2025: 3,551,460 shares bought and 65,000 shares sold, net +3,486,460 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Focus Partners Wealth | 0.00% | New | 3,423,000 | $3.3M |
| State of Wisconsin Investment Board | 0.01% | No change | 3,000,000 | $2.9M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 2,900,000 | $2.8M |
| Bank of New York Mellon Corp | 0.00% | Add +9.2% | 546,000 | $524K |
| Nomura Holdings Inc. | 0.00% | New | 7,460 | $443K |
| Sei Investments Co. | 0.00% | No change | 371,000 | $355K |
| Oppenheimer Asset Management Inc. | 0.00% | No change | 182,000 | $174K |
| Stephens Inc. | 0.00% | No change | 54,000 | $52K |
| MML Investors Services, LLC | 0.00% | New | 49,000 | $47K |
| Mariner, LLC | 0.00% | No change | 42,000 | $40K |
| Commonwealth Equity Services, LLC | 0.00% | New | 20,000 | $19K |
| &partners | 0.00% | Reduce -48.6% | 18,000 | $17K |
| DAVENPORT & Co LLC | 0.00% | No change | 10,000 | $10K |
| Cetera Investment Advisers | 0.00% | No change | 10,000 | $10K |
| CoreCap Advisors, LLC | 0.00% | New | 6,000 | $6K |
| Oddo BHF Asset Management Sas | 0.00% | No change | 225 | $216 |
"% of holder's portfolio" is BIOMARIN PHARMACEUTICAL (BMRN 1.25 05/15/27)'s weight in each manager's 13F, not the share of Biomarin Pharmaceutical (bmrn 1.25 05/15/27) the manager owns.